Earnings Routine +

NervGen Pharma Reports Full Year 2025 Financial Results and Provides Business Updates

Clinical Validation Confirmed, Capital Runway Tightens Ahead of Phase 3 Pivot

By The Northwire Desk — AI Analysis Mar 31, 2026 · 07:45 NGEN · 5.15 Nervgen Pharma Corp.

Executive Summary

The March 31, 2026 release provides full-year 2025 financial results alongside a comprehensive business and clinical update.
Financials show $22.1M in cash and investments, up from $17.3M at year-end 2024, following a $10.05M private placement in November 2025. The reported net loss was $44.1M, heavily weighted by $24.8M in non-cash expenses.
Clinical data confirms the Phase 1b/2a CONNECT SCI trial met its primary endpoint, highlighting an 825% improvement in hand function versus placebo and statistically significant reductions in maladaptive reticulospinal activity.
Regulatory and development timelines are reiterated: FDA End-of-Phase 2 meeting completed, regulatory update expected early Q2 2026, and Phase 3 initiation targeted for mid-2026.
Management changes include the retirement of the CFO, the hiring of a Chief Regulatory Affairs Officer and an SVP of Patient Advocacy, and the termination of a negligible ATM program alongside a voluntary TSXV delisting.

Material Impact

The release is a scheduled confirmation of previously disclosed clinical and regulatory milestones. The 825% functional improvement and primary endpoint success were already communicated in November 2025, meaning the market has largely priced in this positive signal.
The financial disclosure is standard for a pre-revenue clinical-stage biotech. While the headline net loss is large, the actual cash burn is moderate relative to the raised capital. The $22.1M cash balance provides a clear runway to initiate Phase 3 but will not fund trial completion.
Leadership transitions and the TSXV delisting are administrative and operational adjustments that streamline costs but do not alter the fundamental investment thesis.
Overall, the news reinforces the existing trajectory without introducing new, unexpected catalysts or altering near-term valuation drivers.

NGEN · Price

Company Overview

NervGen Pharma is a clinical-stage biopharmaceutical company focused on developing neuroregenerative therapies for neurotraumatic and neurologic conditions.
Flagship asset: NVG-291, a neuroreparative peptide designed to restore neural connectivity and function following spinal cord injury (SCI). The program holds FDA Fast Track and EMA Orphan Drug designations.
The CONNECT SCI Phase 1b/2a trial targets chronic tetraplegia, demonstrating statistically significant improvements in upper-limb function, bladder control, and spasticity reduction, with durability observed up to 364 days post-treatment.

More from Nervgen Pharma Corp.